ESC Medical Systems Receives U.S. FDA Approval for PhotoDerm VL Deep Vessel
Accessory
PR Newswire - May 20, 1998 09:48
ESCMF %MTC %PDT V%PRN P%PRN
YOKNEAM, Israel, May 20 /PRNewswire/ -- ESC Medical Systems Ltd. (Nasdaq: ESCMF) today announced that it has received clearance
from the U.S. Food and Drug Administration (FDA) to market its new PhotoDerm(R) VL deep vessel accessory for non-invasive treatment of
large and deep-lying vessels. This special accessory, based on a unique pulsed Nd:YAG laser, is driven by the PhotoDerm system and uses its
power source and its newly upgraded software package. Like all previous PhotoDerm enhancements, this new attachment is available as an add-on
to new PhotoDerm systems, or as an upgrade to installed units.
Dr. Shimon Eckhouse, President and Chief Executive Officer, commented, "We are excited to introduce the new PhotoDerm VL deep vessel
accessory in the U.S. This upgrade for the PhotoDerm will provide significant advantages to PhotoDerm users. The device gives the doctor the
ability to treat more effectively deeper and larger vessels that were previously hard to treat. In the clinical development work performed by our
investigators, they successfully closed reticular and feeder leg veins non-invasively using this device. This important addition to the PhotoDerm VL
will expand its capability in the large leg vein market."
Dr. Eckhouse continued, "The FDA approval for the pulsed Nd:YAG upgrade is an important opportunity for ESC as we continue to expand and
enhance our product line. This upgrade will be highly beneficial for our installed base as well as provide us with additional sales opportunities to new
customers. We remain focused on providing the latest, most advanced product offerings to our customers and are well-positioned to continue this
technological innovation in our target markets."
ESC Medical Systems Ltd. develops, manufacturers, and markets medical devices utilizing both state-of-the-art lasers and proprietary intense
pulsed light sources technology for non-invasive treatment of varicose veins and other benign vascular lesions, as well as for hair removal, skin
cancer, skin rejuvenation, and other clinical applications. In addition, the company markets surgical laser systems for use in a variety of medical
applications, including ENT, gynecology, and neurosurgery.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, risks associated with the
Company's dependence on a limited number of products, uncertainty of market acceptance, and limited number of customers, as well as risks of
downturns in economic conditions generally, and in the health care industry specifically, risks associated with competition and competitive pricing
pressures, and other risks detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE ESC Medical Systems Ltd.
/CONTACT: Karen Sarid, Chief Financial Officer of ESC Medical Systems,
011-972-4-959-9000; Investors - Robert P. Jones or Meredith Pudalov, or
Press - Richard Dukas of Morgen-Walke Associates, 212-850-5600, ESC Medical
Systems/
(ESCMF) |
